AIM Immunotech (NYSE American: AIM) suspends ATM program after $2.85M sold

Rhea-AI Filing Summary

AIM Immunotech Inc. supplements its prospectus to suspend its at-the-market equity distribution agreement and terminate the continuous offering. The Prospectus had registered the offer and sale of up to $3,409,174 of common stock under an Equity Distribution Agreement with Maxim Group LLC. As of this supplement dated May 19, 2026, the company reports $2,847,151.09 of common stock sold under the EDA and a last reported sale price of $0.4080 per share on May 18, 2026. The supplement states the company will not make any sales under the EDA unless and until a new prospectus supplement is filed; the EDA itself remains in full force and effect.

Insights

Equity Capital Markets Attorney

ATM program sales paused; registration remains available for future use only after new supplement.

The filing suspends the active at-the-market offering and terminates the continuous offering while leaving the Equity Distribution Agreement in force. It confirms $2,847,151.09 has been sold to date against a registered $3,409,174 capacity.

Timing for any resumed sales requires a new prospectus supplement to be filed; cash-flow treatment and intended use of proceeds are not stated in this excerpt. Subsequent filings would disclose any restart or material changes.

Key Figures

Registered offering capacity: $3,409,174 Sold under EDA to date: $2,847,151.09 Last reported sale price: $0.4080 per share +1 more

4 metrics

Registered offering capacity $3,409,174 registered under the Equity Distribution Agreement

Sold under EDA to date $2,847,151.09 sold pursuant to or under the EDA as of May 19, 2026

Last reported sale price $0.4080 per share last reported sale price on May 18, 2026

Prospectus supplement date May 19, 2026 date of this prospectus supplement

Key Terms

Equity Distribution Agreement, at-the-market, prospectus supplement, sales agent

4 terms

Equity Distribution Agreement regulatory

"terms of the Equity Distribution Agreement, originally dated April 1, 2025"

An equity distribution agreement is a formal plan between a company and financial institutions to sell newly issued shares of the company's stock to investors over a period of time. It helps the company raise money gradually, similar to filling a container with water in stages, rather than all at once. For investors, it provides an organized way to buy shares and can influence the stock's supply and price.

at-the-market market

"offering, issuance and sale of up to $3,409,174 shares ... from time to time through our sales agent"

"At-the-market" is a method for companies to sell new shares of stock directly into the open market over time, rather than all at once. It allows companies to raise money gradually, similar to selling slices of a pie instead of the entire pie at once, which can help manage the sale's impact on the stock price. This approach gives investors a steady supply of shares while providing companies with flexible funding options.

prospectus supplement regulatory

"This prospectus supplement supplements, modifies and supersedes"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

sales agent market

"sales agent, Maxim Group LLC"

A sales agent is an individual or firm authorized to sell a company’s products or services on its behalf, typically paid by commission or fees rather than a fixed salary. For investors, who a company uses to reach customers and how well those agents perform affects revenue growth and profit margins — like hiring local independent sellers to expand into new neighborhoods without building stores — so agent quality and cost matter to future cash flow and valuation.

Offering Details

ATM

Offering

Offering Type ATM

Filed Pursuant to Rule 424(b)(5)

Registration No. 333-286319

AMENDMENT NO. 2 DATED MAY 19, 2026

To Prospectus Supplement dated October 30, 2025

(To Prospectus Dated July 3, 2025)

AIM IMMUNOTECH INC.

This prospectus supplement supplements, modifies and supersedes, only to the extent indicated herein, certain information contained in the prospectus dated July 3, 2025 (the “Base Prospectus”), as supplemented by the prospectus supplements dated October 30, 2025 and April 10, 2026 (which, together with the Base Prospectus, the “Prospectus”), relating to the offering, issuance and sale of up to $3,409,174 shares of our common stock, par value $0.001 per share, from time to time through our sales agent, Maxim Group LLC (“Maxim”), pursuant to the terms of the Equity Distribution Agreement, originally dated April 1, 2025 (as amended, the “EDA”).

This prospectus supplement should be read in conjunction with, is not complete without, and may not be delivered or utilized except in connection with, the Prospectus, including all supplements thereto and documents incorporated by reference therein. If there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement. Any information that is modified or superseded in the Prospectus shall not be deemed to constitute a part of the Prospectus, except as modified or superseded by this prospectus supplement.

Our common stock is traded on the NYSE American under the symbol “AIM.” On May 18, 2026, the last reported sale price of our common stock was $0.4080 per share. Under the Prospectus, we registered the offer and sale of up to $3,409,174 of our common stock pursuant to the EDA. As of the date of this prospectus supplement, $2,847,151.09 of our common stock has been sold pursuant to or under the EDA.

We are filing this prospectus supplement to supplement and amend, as of May 19, 2026, the Prospectus, to suspend the EDA and to terminate the continuous offering by us under the Prospectus. We will not make any sales of our common stock pursuant to the EDA unless and until a new prospectus supplement is filed with the Securities and Exchange Commission; however, the EDA remains in full force and effect.

Investing in our common stock involves a high degree of risk. See “Risk Factors” beginning on page 3 of the accompanying Prospectus, the “Risk Factors” section in our most recent Annual Report on Form 10-K, which is incorporated by reference into this prospectus supplement and the Prospectus, and under similar headings in the documents incorporated by reference into this prospectus supplement and the accompanying Prospectus.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

The date of this prospectus supplement is May 19, 2026

FAQ

What did AIM (AIM) do in this prospectus supplement?

The supplement suspends the at-the-market program and terminates the continuous offering. It states the EDA remains in force and no sales will occur under the EDA until a new prospectus supplement is filed.

How much capacity was registered under AIM's EDA?

AIM registered the offer and sale of up to $3,409,174 of common stock under the Equity Distribution Agreement. That dollar amount is the registered aggregate offering capacity stated in the supplement.

How much has AIM sold under the EDA as of the supplement?

As of the prospectus supplement dated May 19, 2026, AIM reports $2,847,151.09 of common stock has been sold pursuant to or under the EDA, as disclosed in the filing.

Will AIM resume sales under the EDA without filing more paperwork?

No. The supplement says AIM will not make any sales under the EDA unless and until a new prospectus supplement is filed with the SEC; the EDA itself remains in full force and effect.